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A B S T R A C T
Triple-negative breast cancers (TNBC), characterized by absence of estrogen receptor (ER),
progesterone receptor (PR) and lack of overexpression of human epidermal growth factor
receptor 2 (HER2), are typically associated with poor prognosis, due to aggressive tumor
phenotype(s), only partial response to chemotherapy and present lack of clinically estab-
lished targeted therapies. Advances in the design of individualized strategies for treatment
of TNBC patients require further elucidation, by combined ‘omics’ approaches, of the mo-
lecular mechanisms underlying TNBC phenotypic heterogeneity, and the still poorly un-
derstood association of TNBC with BRCA1 mutations. An overview is here presented on
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TNBC profiling in terms of expression signatures, within the functional genomic breast tu-
mor classification, and ongoing efforts toward identification of new therapy targets and bi-
oimaging markers. Due to the complexity of aberrant molecular patterns involved in
expression, pathological progression and biological/clinical heterogeneity, the search for
novel TNBC biomarkers and therapy targets requires collection of multi-dimensional
data sets, use of robust multivariate data analysis techniques and development of innova-
tive systems biology approaches.
ª 2010 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
Triple-negative breast cancers (TNBC), defined as tumors that
are negative for estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2 (HER2),
nowadays represent the focusof increasing interest at the clin-
ical, biological and epidemiological level (Irvin andCarey, 2008;
Reis-Filho and Tutt, 2008; Stockmans et al., 2008; Bauer et al.,
2007; Dent et al., 2007), due to the aggressive behaviour of the
tumor, poor prognosis and present lack of targeted therapies
(Mersin et al., 2008; Kaplan et al., 2009; Tan and Swain, 2008).
A better understanding of pathological mechanisms of TNBC
onset and progression, including the still unclear association
withBRCA1mutations, and thecausesofphenotypicheteroge-
neity may allow improvement in planning prevention and de-
signing novel individualized treatments for this breast cancer
subgroup (Goldhirsch et al., 2009).
The new approaches of personalized therapy make use of
specific molecular signatures, biology markers and clinico-
pathological features in tumors and patients. For breast can-
cer, the first clinically used predictive prognostic markers,
arising from elucidation of hormonal regulation, were ER/PR
which led to the tailoring of endocrine/anti-hormonal ther-
apy. The first cytogenetic predictor for breast cancer treat-
ment has been the HER2 (HER2/neu, c-erbB2) gene
amplification and protein overexpression. A monoclonal hu-
manized antibody, trastuzumab (Herceptin), is currently
used in the treatment of breast cancer patients presenting
with HER2 positivity. Recent scientific and technological ad-
vances nowadays provide a large inventory of candidate
DNA, RNA, and protein biomarkers, as well as a range of me-
tabolites and networks of cell signaling pathways (Swanton
and Caldas, 2009; Bathen et al., 2007; Gast et al., 2009; Chen
and Wang, 2009), all potential candidates for disease risk as-
sessment, screening, diagnosis, prognosis, prediction of ther-
apy response and selection of personalized therapy.
Nevertheless, such predictors of TNBC prognosis and targeted
therapy are presently ill-defined, making the true challenges
of this disease still unmet. A critical step in the expansion of
personalized therapy involves development of newmolecular
imaging tools, adjusted to monitor specific molecules and
pathways involved in cancer associated signaling and metab-
olism. The emerging field ofmolecular imaging (He et al., 2003;
Belkic, 2004; de Vries et al., 2007; Hospers et al., 2008) enables
translational medicine from drug discovery via pre-clinical to
clinical research and development and finally, to the clinical
practice. Imaging biomarkers have proven utility in the
spectrum from intact cells, to experimental tumors in small
animals, to patients. Biomarkers are useful in longitudinal
quantification of the course of malignancy and therapy re-
sponse, as well as in early identification of cancer patients
and in therapy decision. In conclusion, the success of bio-
markers depends on our ability to reveal critical cancer related
molecular events and the mechanisms of action of targeted
therapy (Tan and Swain, 2008), on how effectively a specific
biomarker is related to other biomarkers and to a specific dis-
ease condition, as well as on sensitivity and specificity of the
available analytical and imaging tools (Dowsett and Dunbier,
2008).
In the search for TNBC biomarkers of diagnosis, prognosis
and prediction of therapy response, high dimensional data
sets can be generated from different modern ‘omics’ related
analyses, such as microarrays in genomics, proteomics and
MR-based metabolomics. The complexity of aberrant molecu-
lar patterns involved in expression, pathological progression
andbiological/clinicalheterogeneityof theTNBCphenotypere-
quires collection of multi-dimensional data sets, use of robust
multivariate data analysis techniques (Bishop, 1995; Duda
et al., 2001; Vapnik, 2002) and development of innovative sys-
tems biology approaches (Chuang et al., 2007; Goh et al., 2007;
Pujana et al., 2007; Shen et al., 2009; Fitzgerald et al., 2006;
Aebersold et al., 2009). The combination of these progressively
more potent technological toolsmay open newperspectives to
the fight against this challenging breast cancer subgroup with
worse prognosis and still limited therapy options.
2. Clinical features of TNBC and limitations of
current treatment options
2.1. Incidence, recurrence and outcome
According to current estimates, TNBC accounts for 10e17% of
all breast carcinomas, depending on thresholds used to define
ER and PR positivity and HER2 overexpression (Reis-Filho and
Tutt, 2008). In different series and patient populations TNBC
may range 6e28% of breast cancers (Haffty et al., 2006;
Rakha et al., 2007; Dent et al., 2007; Kwan et al., 2009), but
even higher incidence rates are reported for some ethnical
groups such as African Americans and for younger patients
(Stead et al., 2009; Trivers et al., 2009; Lund et al., 2009;
Morris et al., 2007; Carey et al., 2006).
Despite its relatively small proportion among all breast
cancers, TNBC is responsible for a relatively large proportion
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of breast cancer deaths, due to its generally aggressive clinical
course. In a retrospective study on a cohort of 1601 patients
with breast cancer (Dent et al., 2007), a subgroup of 180women
with TNBC had a significantly lower mean age at diagnosis
(P< 0.0001), increased likelihood of distant recurrence (hazard
ratio vs other breast cancer phenotypes equal to 2.6; 95% con-
fidence interval (CI) 2.0e3.5; P < 0.0001) and death (hazard ra-
tio 3.2; 95% CI 2.3e4.5; P< 0.001) within five years of diagnosis,
but not thereafter. Also, patients with TNBC were more likely
to present with larger mean tumor size (P < 0.0001) and
histological tumor grade (P < 0.0001). Although data on differ-
ential lymph node spread in TNBC and other breast cancer
subgroups are still conflicting (Dent et al., 2007; Reis-Filho
and Tutt, 2008; Rakha et al., 2008), an interesting feature was
the substantial lack of correlation between nodal metastasis
and tumor size among women with tumors smaller than
50 mm (Dent et al., 2007) (Fig. 1A). A similar trend was also
found in BRCA1-associated tumors (Fig. 1B), as discussed in
Section 3.2 (Foulkes et al., 2003a). The patterns of recurrence
in TNBC were qualitatively different from the non-TNBC
Figure 1 e Lack of correlation between tumor size and nodal status among (A) triple-negative breast cancers (TNBC) with tumor size smaller than
50 mm (c2 test for trend: P[ 0.47 for TNBC; P< 0.0001 for other breast cancer subtypes) and (B) BRCA1-associated breast cancers (c2 test for
trend: P [ 0.183 for BRCA1-associated tumors; P< 0.0001 for BRCA2-associated breast tumors and for breast tumors in non-carriers). ND
positive nodal status (at least one positive lymph node). Graphs adapted from Dent et al. (2007) and (Foulkes et al. 2003a).
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group. In the former, the risk of distant recurrence peaked at
approximately three years and declined rapidly thereafter,
whereas in the other breast cancer types the recurrence risk
seemed to be constant over time (Dent et al., 2007).. TNBC
has a preference for visceral metastases (Liedtke et al., 2008).
It should be emphasized that TNBC currently includes
a heterogeneous group of tumors. Already by simplemorphol-
ogy, a group of patients with TNBC can be identified who have
a more favourable outcome, for example patients with inva-
sive adenoid cystic, apocrine and typical medullary tumors
(Japaze et al., 2005; Azoulay et al., 2005; Orlando et al., 2005).
Even within the relatively homogeneous group of patients
with triple-negative invasive ductal carcinoma, patients with
higher or lower risk may be identified, based on specific mo-
lecular markers (Viale et al., 2009).
2.2. Current cytotoxic treatment options
Several studies support the notion that primary TNBC is a che-
mosensitive disease. However, although TNBC is associated
with enhanced pathological complete response to neoadju-
vant chemotherapy (von Minckwitz et al., 2008), these cancers
show worse survival due to higher relapse among those with
residual disease after chemotherapy (Liedtke et al., 2008;
Carey et al., 2007). In fact, despite the high sensitivity to che-
motherapy, TNBC patients with truly chemosensitive disease
still represent aminority among all TNBC patients. In themet-
astatic setting, patients progress quickly on first-, second-,
and third-line palliative treatment (Kassam et al., 2009).
As triple-negative disease is often characterized by an im-
paired DNA repair process, cytotoxic agents inducing DNA
damage may be of specific value. Recent small and non-ran-
domized studies have shown promising results with cisplati-
num, both in the neoadjuvant and metastatic setting (Byrski
et al., 2009; Sirohi et al., 2008), although the clinical response
to paclitaxel and cyclophosphamide may also be high
(Rouzier et al., 2005). A new approach under clinical trial in-
cludes the use of ixabepilone, a microtubule inhibitor
(Thomas et al., 2007; Baselga et al., 2009b).
Larger prospective clinical trials are needed to determine
the optimal cytotoxic treatment for TNBC.
3. Molecular profiling of triple-negative breast
cancers
3.1. The relationship between TNBC and basal-like
breast cancer
Molecular profiling of human breast cancers by gene expres-
sion assays provided in the last decade new grounds to
a clearer understanding of the heterogeneous nature of these
tumors with promising trends for outcome prediction and de-
velopment of individualized therapies (van’t Veer et al., 2002;
van de Vijver et al., 2002; Perou et al., 2000; Sørlie et al., 2003;
Chang et al., 2005). The gene expression based classification
proposed by Perou and Sørlie ten years ago originally defined
six subtypes (Perou et al., 2000; Sørlie et al., 2003). Three of
these were characterized by expression of ER and luminal ep-
ithelial cell related genes (Luminal A, Luminal B and Luminal C)
while the remaining three groups, basal-like, ErbB2þ and nor-
mal-like, showed an expression phenotype more similar to
myoepithelial/basal epithelial cells. The ErbB2þ tumors were
in particular characterized by high expression of ErbB2 and
genes located adjacent to the ErbB2 locus and the normal-
like subgroup showed expression patterns similar to normal
breast tissue samples. Although this seminal work was based
on analyses on neoadjuvantly treated breast carcinomas, the
main findings have since been validated in numerous inde-
pendent cohorts and these intrinsic subtypes show different
mutation patterns, prognosis and routes of progression
(Sørlie et al., 2003; Calza et al., 2006; Hu et al., 2006; Langerod
et al., 2007; Naume et al., 2007; Smid et al., 2008; Parker et al.,
2009). Later, using array comparative genomic hybridization
(aCGH), several investigators have found that genomic alter-
ations seem to be more frequent in some of the intrinsic sub-
classes (Chin et al., 2006; Fridlyand et al., 2006; Bergamaschi
et al., 2006). Of particular interest to this review, basal-like tu-
mors frequently have complex rearrangements with higher
numbers of gains and losses compared to luminal subtypes
(Chin et al., 2006; Fridlyand et al., 2006; Bergamaschi et al.,
2006), although there is evidence of a subgroupof basal-like tu-
mors with low genomic instability (Chin et al., 2007). Such het-
erogeneity is recognized by gene expression classification as
well (Kreike et al., 2007) and multiclonal basal-like tumors
have been described (Navin et al., 2010). Recently a distinct
type of rearrangements dominated by genomewide duplica-
tions was identified in a selection of basal-like tumors and
cell-lines (Stephens et al., 2009), suggesting that these types
of tumors represent a distinct type of breast carcinomas with
a unique path of progression (Navin et al., 2010; Dalgin et al.,
2007). In addition, the emerging knowledge of a cellular hierar-
chy in the breast supports the theory that basal-like tumors
may have a distinct etiology (Villadsen et al., 2007; reviews
in: Sims et al., 2007; Polyak, 2007).
Immunohistochemistry (IHC) is frequently used to explore
the distribution of the molecular subtypes by using formalin-
fixed, paraffin-embedded tissues from larger cohorts of breast
cancer patients. The ultimate selection of surrogate markers
is an ongoing debate and a consensus for an appropriate panel
still has to be reached (Rakha et al., 2008). Triple negativity is
often used to identify basal-like tumors (Kreike et al., 2007) al-
though a supplement of additionalmarkers has superior prog-
nostic value (Cheang et al., 2008; Nielsen et al., 2004). Triple
negativity as a selection criterion is highly sensitive of basal-
like tumors, but not specific as both luminal, ErbB2þ and nor-
mal-like tumors (as identified by gene expression) can be ste-
roid receptor negative and HER2 non-amplified (Naume et al.,
2007). The heterogeneity of TNBC is acknowledged and in-
cludes both basal-like and non-basal-like tumors (Rakha
et al., 2009; reviewed in Hurvitz and Finn, 2009). IHC-based
studies use different markers to define their basal-related tu-
mors and the lack of a systematic classification schememakes
comparison of results difficult. Acknowledging the differences
between the two terms is important in clinical studies aiming
to identify prognostic markers and targets for therapy for
these important subgroups of breast carcinomas.
Morphologically basal-related tumors are typically of high
histological grade with a high mitotic count and they fre-
quently exhibit geographic tumor necrosis, central scar,
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pushing margings and/or stromal lymphocyte enrichment
(Fulford et al., 2006; Livasy et al., 2006; Rakha et al., 2006). Al-
though most TNBCs are classified as ductal carcinomas, tu-
mors of ‘special types’ such as medullary and adenoid cystic
carcinoma fall into this category as well (Bertucci et al., 2006;
Jacquemier et al., 2005; Vincent-Salomon et al., 2007; Weigelt
et al., 2008). Many of the clinical features of the basal-like phe-
notype are similar to those of TNBC (see Section 2.1), including
shorter relapse-free and overall survival times compared with
other types of breast cancers, a tendency toward visceral ver-
sus bone metastasis (Rodriguez-Pinilla et al., 2006; Rakha
et al., 2008), and over-representation in BRCA1 mutation car-
riers (Foulkes et al., 2003b; Haupt et al., 2010).
3.2. The BRCA-associated triple-negative breast cancers
Following identification, mapping and cloning of the two ma-
jor breast cancer predisposing genes, BRCA1 (chromosome
7q21) and BRCA2 (chromosome 13q12) (Hall et al., 1990; Miki
et al., 1994; Wooster et al., 1995), increasing attention has
been focused on biological and molecular characteristics of
breast cancers in BRCA- and non-BRCA1/2 (BRCAX) mutation
carriers, in relation to carcinogenesis, disease progression
and outcome (Breast Cancer Linkage Consortium, 1997;
Lakhani et al., 1998, 2002; Verhoog et al., 1998; Moller et al.,
2002; Narod and Foulkes, 2004; Robson et al., 2004;
Brekelmans et al., 2006; Bonadona et al., 2007; Moller et al.,
2007; Honrado et al., 2007; Melchor and Benitez, 2008).
Major clinical characteristics of breast cancer in BRCA1
mutation carriers, compared with age-matched patients un-
selected for family history were envisaged to be younger age
at onset (Robson et al., 2004; Cornelis et al., 1995), frequent bi-
lateral occurrence (Hall et al., 1990; Ford et al., 1994; Easton
et al., 1995), high frequency of ductal histotype cancer, al-
though with a relative excess of medullary and atypical med-
ullary histotypes, higher overall grade and worse
histoprognostic features (Breast Cancer Linkage Consortium,
1997; Lakhani et al., 1998, 2002; Verhoog et al., 1998;
Jacquemier et al., 1995; Marcus et al., 1996; Eisinger et al.,
1996). Histopathological characteristics frequently detected
in BRCA1-associated breast cancers are higher mitotic counts,
greater degree of nuclear polymorphism and less tubule for-
mation. However, multifactorial analysis of histopathological
differences between sporadic breast cancers and cancers in-
volving BRCA1 and BRCA2 mutations (Lakhani et al., 1998)
demonstrated that many of these features were linked with
each other, the only factors independently associated with
BRCA1 being high mitotic count, presence of lymphocytic in-
filtrate and presence of smooth noninfiltrative pushig border.
A similar multifactorial analysis showed that reduction in tu-
bule formation (together with higher overall grade) and pres-
ence of continuous pushing margins were also significantly
associated with BRCA2-related breast cancer.
Combined immunohistochemical and molecular analyses
of cancer-associated genes and encoded proteins carried out
within a large collaborative study of the Breast Cancer Link-
age Consortium (Breast Cancer Linkage Consortium, 1997;
Lakhani et al., 1998, 2002) showed that breast cancers in pa-
tients with BRCA1 germline mutation are more often nega-
tive for ER, PR and HER2 and are more likely to be positive
for p53 protein compared with controls. BRCA2 tumors did
not show, instead, any significant difference in the expres-
sion of these proteins. In fact, only 10% of BRCA1-mutated
cancers showed positive staining for ER compared with 66%
of BRCA2 and control tumors; positivity to PR was 21% for
BRCA1-cancers compared with 55e61% for BRCA2 and con-
trol cancers; and a low positivity (3%) was found for HER2
in both BRCA1 and BRCA2 tumors. Multiple logistic regres-
sion analysis of the immunohistochemical factors (ER-nega-
tive, PR-negative and HER2-negative) and morphological
features that were significant predictors of BRCA1 status in-
dicated that the ER status was the most significant risk factor
(Lakhani et al., 2002). On the other hand, the expression of ER
is known to inversely correlate with tumor grade (Henderson
and Patek, 1998) and is reported as one of the most impor-
tant prognostic and predictive markers for breast cancer
(Osborne, 1998).
Unsupervised cluster analysis of non-BRCA1/2 breast can-
cer families (50 probands) demonstrated heterogeneity of
BRCAX families (Honrado et al., 2007). In fact twomain groups
were identified, one of high grade and ER-negative (50%) and
one of low-grade and ER-positive tumors (50%). These two
groups were in turn subdivided into five subgroups: three
among the high-grade and two among the low-grade groups;
one overexpressing HER2 (18%); one with a basal-like pheno-
type (14%); one with a normal breast-like phenotype (18%);
a luminal A subgroup (36%) and a luminal B subgroup (14%).
At the molecular level, BRCA1 and BRCA2 proteins are
known to be involved in DNA repair (Scully, 2000), cell cycle
checkpoint control through regulation of p53 activity (Liu
and Kulesz-Martin, 2001) and maintenance of global chromo-
some stability (Venkitaraman, 2002).
Amore completemolecular portrait has been recently con-
solidated for the majority of breast tumors in BRCA1-mutated
patients. This general genomic and proteomic profile typically
includes lack of (or low) expression of hormone receptors,
HER2 and BCL2 and overexpression of p53, EGFR and basal
cytokeratines (CK 5/6) (Lacroix and Leclercq, 2005; Honrado
et al., 2006), associated at clinical level with high frequency
of ductal type, high proliferation rate, high histological grade
andmanifested lymphocyte infiltration. The reportedmolecu-
lar features are also characteristic to basal-like carcinomas
(Perou et al., 2000; Gorski et al., 2009), although overlap of tu-
mor biological features between BRCA1-associated and
basal-like cancer subtype is not complete (Dawson et al.,
2009). Depletion of BRCA1 affects differentiation and en-
hances proliferation of mammary epithelial cells, as also con-
firmed by studies on animal models (Kubista et al., 2002;
Furuta et al., 2005; Bradley and Medina, 1998).
Over-representation of the TNBC phenotype in BRCA1-as-
sociated tumors allows a rational retrospective interpretation
of a series of similarities separately reported for the clinico-
pathological features of these two breast cancer subgroups.
Of particular interest in this respect are the younger age of
the first breast cancer event; high histopathological grade;
some common morphological features (e.g. smooth noninfil-
trative pushing border); and the above mentioned lack of cor-
relation between tumor size and nodal status (Fig. 1).
Tumors arising from BRCA1 and BRCA2 mutation carriers
appear to have specific pathological and gene expression
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profiles (Honrado et al., 2006), while BRCAX tumors are in-
creasingly believed to originate frommultiple distinct genetic
events (Lacroix and Leclercq, 2005). The use of microarray
technology in the evaluation of the immunophenotypic fea-
tures of hereditary breast cancer (Palacios et al., 2003)
revealed distinct characteristics in BRCA1 and in non-
BRCA1/2 tumors, whereas BRCA2 tumors presented interme-
diate patterns. No cases of HER2 amplification and/or overex-
pression were found by the authors, except in sporadic breast
cancers.
The BRCA1 tumor suppressor gene and the HER2 oncogene
are located in close proximity on the long arm of chromosome
17 (17q11e21), but the aggressive pathological features of
BRCA1-associated tumors appear unrelated to amplification
of the adjacent HER2 oncogene (Grushko et al., 2002).
Themolecular mechanisms responsible for tissueespecific
carcinogenesis in BRCA1-associated breast cancer are still to
be clarified. The existence of common genomic features in
the basal-like phenotype of BRCA1-associated breast cancers
and that of normal breast stem cells recently suggested that
BRCA1may act as a humanmammary stem cell fate regulator
(Foulkes, 2004; Liu et al., 2008). In particular, the BRCA1 ex-
pression was found to be required for the differentiation of
ER-negative stem/progenitor cells to ER-positive tumoral cells
and was proposed to result in the accumulation of genetically
unstable breast stem cells, providing prime targets for further
carcinogenic events (Liu et al., 2008). On the other hand, the
basal-like molecular subtype can also be found in sporadic,
BRCA2- and BRCAX-associated cancers, although with
a much lower frequency (10e20% compared with up to 90%
in BRCA1-classified cancers). A critical role of the BRCA1 pro-
tein has also been shown in the development of these basal-
like carcinomas (Melchor and Benitez, 2008 and ref. therein).
Attention has been focused on the possible molecular
mechanisms underlying the very low or inexistent overex-
pression (and gene amplification) of HER2 (0e3%) in BRCA1/
2-associated breast cancers (Lakhani et al., 2002; Palacios
et al., 2003; Grushko et al., 2002) compared with that
(15e20%) in BRCAX-associated tumors (Honrado et al., 2007).
A possible co-deletion of HER2 and BRCA1 loci (Johannsson
et al., 1997) would not explain the lack of HER2 overexpression
in BRCA2-associated cancers. It has been postulated (Melchor
and Benitez, 2008) that the defects in the DNA repair system
associated with deleterious BRCA1 mutations may not be
compatiblewith the proliferation stress of the aberrant signal-
ing cascade triggered by HER2 tyrosine phosphorylation and
therefore, under these conditions, HER2-overexpressing can-
cer cells are unlikely to survive.
Figure 2 e Integration of predictive expression signatures and altered cell signaling patterns in the search for pathway-driven tumor therapeutics
and bioimaging.
M O L E C U L A R O N C O L O G Y 4 ( 2 0 1 0 ) 2 0 9e2 2 9214
4. Imaging features
Examinations of women of 50 years and over (Dent et al., 2007)
showed that patients with TNBC had amuch lower proportion
(P ¼ 0.0008) of breast cancers first detected by mammography
or ultrasound (19.5%) than patients with other breast cancers
(36.5%). This result supported the conclusion that in a mam-
mography screening programme offered to women over 50
years of age, TNBC often presents as an interval cancer, in
agreement with a previous study (Collett et al., 2005). This fea-
ture, which may relate to differences in breast density, or to
a rapid tumor growth in relation to the screening interval,
warrants further investigations to optimize multimodality
and periodicity of screening events in surveillance programs
addressed to women belonging to populations at high risk of
TNBC. Mammographic examinations on premenopausal
women showed that a circumscribed mass (without spicu-
lated margins) and absence of microcalcifications were most
commonly presented features in TNBCs compared with can-
cers of other subtypes (Yang et al., 2008; Wang et al., 2008).
The absence of spiculated masses and pleomorphic microcal-
cifications suggested thatmammographymay not be the ideal
tool for early detection of TNBCs.
The use of dynamic contrast-enhanced magnetic reso-
nance imaging (MRI) showed that 97% of TNBC lesions were
of mass-type, with typical malignant signal enhancement ki-
netics (Chen et al., 2007). Correlations between MRI and path-
ological findings recently investigated in surgically confirmed
TNBC, compared with ER-positive, PR-positive and HER2-neg-
ative breast cancers (Uematsu et al., 2009), showed that the
former subtype was significantly associated with high histo-
logic grade, unifocal lesions, smooth mass margin, rim en-
hancement, persistent enhancement pattern, and very high
intratumoral signal intensity on T2-weighted MR images.
The last feature was significantly associated with intratu-
moral necrosis, a characteristics typically associated with
poor prognosis.
These radiological imaging methods, and their possible
combination with functional imaging approaches, such as dif-
fusion-weighted MRI (Bogner et al., 2009), may assist in TNBC
prognosis and treatment planning.
A study on fluorodeoxy-glucose-positron emission tomog-
raphy (FDG-PET) characteristics showed a sensitivity of 100%
for detection and a higher FDG uptake in TNBC compared
with ER-positive/PR-positive/HER-negative tumors, suggest-
ing enhanced glycolysis in the former, more aggressive sub-
group (Basu et al., 2008). Further studies should be devoted
to better clarify the potential of PET approaches in evaluating
prognosis and predicting therapy response in TNBC.
Finally, non invasive in vivo localized magnetic resonance
spectroscopy (MRS) examinations and high resolution magic
angle spinning (HR-MAS) MRS analyses on surgical speci-
mens may offer new perspectives to the characterization of
metabolic profiles of breast cancers, also in relation to lym-
phatic spread, grade and hormone receptor status (Bathen
et al., 2007; Podo et al., 2007; Sitter et al., 2009; Giskeødega˚rd
et al., 2010).
Table 1 e Possible agents for TNBC targeted therapy.
TNCB biomarkers Major affected
signaling pathways
or cellular process
Biological effects Proposed TNBC
therapeutic agents
EGFR (or HER1)
tyrosine kinase
MAP kinase
(RAS-RAF-MEK1/2 e ERK1/2)
Cell proliferation Cetuximab; Erlotinib; Gefitinib
c-KIT PI3K-AKT Cell survival Imatinib; Sunitinib; Dasatinib
TOP2A
(topoisomerase II a)
DNA replication Chemotherapy response Antracyclins, Metoxantrone
and etoposide
c-Myc Gene transcription Cell growth 10058F4 small molecule
compound
(potential)
Cell-cycle control Angiogenesis
Apoptosis
PARP (poly(ADP-ribose)
polymerase)
BRCA1eassociated cancers
DNA repair Apoptosis Olaparib
VEGF/VEGFR
(tumor endothelial cells)
Hypoxia-induced
metabolic pathways
Angiogenesis Bevacizumab; Sunitinib;
Sorafenib
p53 Cell-cycle control Proliferation/
apoptosis
Not available
Src kinase STAT-pathway; PI3K; FAK Cell proliferation;
cell survival; angiogenesis;
cell invasion, adhesion
and migration
Dasatinib
TGFb T-reg activation Repression of
antitumor immunity
Anti-TGF-b Ab; anti-sense
oligonucleotides;
selective TK inhibitorsEpithelial-mesenchimal
transition (EMT)
Tumor cell motility, blood borne
metastasis
Alpha B-crystalline MAPK/ERK Anchorage independent
cell growth; increased migration
and invasion
ERK kinase inhibitors
(potential)
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5. Towards pathway-driven TNBC therapeutics
5.1. Concepts and tools
Classification of tumors by molecular profiles and increasing
knowledge on altered regulation of gene expression at the
translational, transcriptional and epigenetic levels (Fig. 2)
allowed in the last decade the identification of possible novel
markers and targets for pathway-driven therapeutics in tu-
mors (Cleator et al., 2007; Tan and Swain, 2008; Dowsett and
Dunbier, 2008; Swanton and Caldas, 2009; Bouchalova et al.,
2009; Goldhirsch et al., 2009; Bosch et al., 2010).
Accumulation of defects in cellular regulationmechanisms
is the underlying cause for disease heterogeneity and differen-
tial response to treatment, also within a subgroup like TNBC.
This can be at the level of gene amplification, methylation, ex-
pression, mutations, or other as yet unknown regulation
mechanisms. Activation of an oncogene can increase activity
in downstream pathways without necessarily requiring over-
expression of proteins in these pathways. Beyond the wide di-
versity in the combination of overexpressed pathways, the
basal-like subtype is reported to be associated with increased
activity of the HER1, RAS, CTNNB1, TP53 and E2F3 pathways
(Bild et al., 2009). Other notable characteristics of TNBC include
a high level of proliferative genes, including Ki-67, basal cyto-
keratins such as CK5 and CK17, caveolin-1, alpha B-crystallin,
frequent p53 mutations, Retinoblastoma (Rb) pathway inacti-
vation, high c-kit expression, reduced DNA repair capability,
increased angiogenesis and TGF-regulated genes (Schneider
et al., 2008).
The above mentioned TNBC biomarkers and characteris-
tics are known to have relevant implications on cell signaling
pathways, tumor metabolism, evasion of cell-cycle control,
invasion and metastasis, as summarized below (Table 1).
Understanding the relations between these potential
markers may help to appreciate the heterogeneity of these tu-
mors and improve the response prediction to single agents
and combination treatments.
Themultiplicity of ongoing efforts to identify, characterize,
and validate new biomarkers and therapy targets for TNBC
(Bosch et al., 2010) shows the complexity of such a goal and
the need for well designed and rigorous studies, at all levels
of investigation, to resolve conflicting results, which halt or
slow down the advancement of this field. Systems biology
can be an important tool for elucidating crosstalk between
pathways and understanding temporal effects of tumor
behaviour.
5.2. Targetable pathways and cellular processes
Proliferation and death are uncommon features for non-tu-
morigenic, healthy cells and therefore these events are under
tight control atmany levels. Fluxes throughpathwaysare intri-
cately balanced by stimuli of different nature and checked by
multiple feedback control mechanisms at cellular, tissue, or-
gan and organism level. Backupmechanisms to assure proper
functioning in case the first level of control goes awry are pres-
ent in normal cells. Tumor cells have accumulated defects that
allow them to bypass the normal control mechanisms that
check proliferation. For tumor cells to grow and proliferate,
they must evade checks on several cellular controls. The in-
creased energy requirement of tumor cells causes metabolic
stress at the level of nutrient and oxygen supply. The accumu-
lation of gene amplifications, translocations and mutations
must evade cellular control on DNA damage during cell cycle
checkpoints. Whereas most cells can only survive with close
contacts to theirneighbours,metastatic tumorcellsmustover-
come the apoptosis directed controls associated with anoikis.
Within one tumor, large differences exist in local environment
that may cause cells at the edge to proliferate, while cells that
are deprived of nutrients and oxygen may undergo necrosis,
therewith exposing their neighbours to stressful conditions.
Histopathology canmake this cellulardiversity visible, butmo-
lecular techniques like gene expression profiling and proteo-
mics determine the average of all these microenvironments
in a selected tissue sample.
5.2.1. Metabolism
Rapidly growing tumors need a high supply of nutrients and
oxygen. Tumor cells have developed several mechanisms to
satisfy their needs in these respects, varying from assuring
a good nutrient supply by stimulation of new blood vessels
formation, to adjustments in glucose metabolism and
methods to survive at low oxygen concentrations. Although
debatable whether it is the only cause, hypoxia promotes via
the Hypoxia-inducible factor 1 (HIF-1) a change in metabolic
pathways in tumor cells (Marin-Hernandez et al., 2009). Tu-
mor cells derive most of their energy from glycolysis rather
than from oxidative phosphorylation, even though the yield
in ATP per glucose is reduced from 36 for the aerobic oxidative
phosphorylation to 2 for the anaerobic process. Furthermore,
the formation of lactic acid poses challenges for pH homeosta-
sis in the cell. Glutaminolysis is used to produce sufficient
amounts of precursors for synthesis of small molecule build-
ing blocks to sustain proliferation, which are usually provided
by the TCA cycle. This shift in metabolic pathways makes tu-
mor cells less sensitive to hypoxia and reactive oxygen
species.
The flux throughmetabolic pathways is regulated at differ-
ent levels, ranging from de novo synthesis of proteins to acti-
vation of limited duration of proteins via covalent
modification and allosteric activation or inhibition by sub-
strates or products of a pathway. In regulation of the balance
between anabolic and catabolic pathways, the protein kinases
Akt, with constituents of the Akt pathway like mTor, and
AMPK play crucial roles. Akt activity for example is stimulated
by a multitude of growth factors via receptor tyrosine kinase
induced signaling, transmitted by PI3K, and by small interme-
diate metabolites like retinoic acid and prostaglandin. AMPK
senses a low energy state by the AMP/ATP ratio. Not only do
Akt and AMPK directly regulate the balance between the path-
ways, they also affect levels of tumor suppressor protein p53
by either promoting its degradation or stimulating its synthe-
sis. Discussing the subtilities of the pathways and their regu-
lation is too farfetched for this review. The role of p53 in
regulation of metabolism in tumor cells has been recently
reviewed (Vousden and Ryan, 2009).
Whereas an abundant energy supply leads to cell prolifer-
ation, an insufficient energy supply leads to autophagy and
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cell death. Autophagy is part of everyday normal cell growth
and development eliminating malfunctioning proteins,
reshaping membranes, recycling of receptors, etc. During nu-
trient starvation, autophagy can provide additional energy or
building blocks by the breakdown of non-vital cell compo-
nents, ensuring that vital processes can continue. mTor plays
an important regulatory role in this process. Prolonged starva-
tion will lead to cell death and necrosis, events often found in
tumors. The products that result from necrosis, pose addi-
tional stress on neighbouring cells and lead to induction of
the NFkB pathway.
5.2.2. Evasion of cell-cycle control
Under conditions of sufficient nutrient supply, proliferation
can take place. In most non-tumorigenic cells, the G0 phase
is the default state. Strong stimuli are required to leave this
state.When it occurs, the steps of the cell cycle are tightly con-
trolled. In many cancer cells, the control on the cell cycle pro-
gression is faulty, permitting cells with errors in DNA to
proceed to the next step of the cycle and producemore genetic
diversity. TNBC suffers from frequent mutations in the tumor
suppressor protein p53 and in Rb pathway inactivation
(Schneider et al., 2008), whereas mutations in c-Myc are rela-
tively rare (Rodriguez-Pinilla et al., 2007).
The Rb pathway in the G1/S checkpoint is activated by
phosphorylation of retinoblastoma by cyclin/CDK complexes,
leading to the activation of transcription factor E2F. The activ-
ity of cyclin/CDK is stimulated by the proto-oncogene Myc,
which in turn is activated by e.g. the HER1 (or EGFR) pathway.
Myc regulates the expression of a multitude of proteins
(Bouchalova et al., 2009).
Upregulation of CDNK2A, often observed in TNBC, inhibits
the CDK2 activity and therewith promotes inactivation of
p53, resulting in blockage of the senescence and apoptosis
pathways. The increased expression of CDNK2A and related
CDNK2’s allows bypassing the checks in cell-cycle control in
theRbpathwaysandpromotesprogression into theG1/Sphase
(Schneider et al., 2008;Musgrove and Sutherland, 2009). BRCA1
and BRCA2 also have a function in cell-cycle control via their
regulation of p53 activity (Liu and Kulesz-Martin, 2001). After
amplification of DNA, the daughter strandsmust be separated.
Topoisomerases, notably TOP2A, are essential in this process.
TOP2A amplification is most frequent in HER2-overexpressing
tumors (Durbecq et al., 2003) and although a triple-negative
phenotype was associatedwith TOP2A expression, no amplifi-
cation was found (Tan et al., 2008).
DNA damage repair is not only essential during cell divi-
sion, but also is a continuous process. Cells are exposed to fac-
tors that can cause damage to their DNA. These defects must
be repaired (Jackson and Bartek, 2009). When that is not possi-
ble, cells go into apoptosis. Exposing cells to chemotherapy or
radiation therapy causes irreparable damage inmost cells, but
some aremore resistant than others. BRCA1 and BRCA2 are in-
volved in DNA repair. Cells lacking either of these proteins are
more susceptible to poly(ADP-ribose) polymerase (PARP) in-
hibitors (see below).
5.2.3. Invasion and metastasis
Cells thrive only when they are in close contact with neigh-
bouring cells and the extracellular matrix. When cells become
detached from their natural environment, they die by anoikis.
Tumor cells escape this fate when they undergo the epithelial
mesenchymal transition (EMT) to acquire amesenchymal-like
phenotype and can become invasive. The essential features of
EMT are the disruption of intercellular contacts and the en-
hancement of cell motility, thereby leading to the release of
cells from the parent epithelial tissue. The EMT enables cells
to penetrate vessel endothelium and enter the circulation to
form distantmetastasis (Guarino et al., 2007). The Basal B sub-
group of breast cancer has enhanced invasive properties and
a predominantly mesenchymal gene expression signature,
distinct from subgroups with predominantly luminal (termed
Luminal) or mixed basal/luminal (termed Basal A) features
(Guarino et al., 2007). Epithelial mesenchymal transition has
long been associated with breast cancer cell invasiveness
(Neve et al., 2006). During EMT the abundance of the proteins
N-cadherin, Vimentin, several metalloproteinases and tran-
scription factors like Snail1 (Snail), Snail2 (Slug) increases,
while decreased concentrations are observed for E-cadherin,
Desmoplakin, Cytokeratin and Occludin. Several intercon-
nected transduction pathways and a number of signalingmol-
ecules potentially involved have been identified. Growth
factor driven receptor tyrosine kinases play an important
role, but Wnt, NFkB, integrin and TGFb signaling also contrib-
ute (Lee et al., 2006; Giampieri et al., 2009). Most of these path-
ways converge on Akt (Iliopoulos et al., 2009) and on the
downregulation of the epithelial molecule E-cadherin, an
event critical in tumor invasion and a ‘master’ programmer
of EMT (Guarino et al., 2007).
EMT is accompanied by changes inside the cells, such as
reorganisation of the actin cytoskeleton and regulation of fo-
cal adhesion (reviewed by Jiang et al., 2009).
5.2.4. Integration of signals
As illustrated above, different processes take place either si-
multaneously or sequentially in tumor cells. Signals from
the environment can also lead to conflicting stimuli as input.
The different routes converge on central signaling hubs. Coor-
dination of the processes requires a tight orchestration of
these events, with Akt, mTor, p53, HIF-1, NFkB and Myc being
some of the leading conductors, though at different time
scales.
Whereas the Akt/mTor kinases regulate rapid responses of
short duration, proteins like p53, Myc and HIF influence the
expression of large numbers of genes.
HIF-1alpha is involved in the activation of numerous cellu-
lar processes including resistance against apoptosis, overex-
pression of drug efflux membrane pumps, vascular
remodeling and angiogenesis, as well as EMT and metastasis
(Marin-Hernandez et al., 2009) and in immune reactions and
inflammatory response (Hellwig-Burgel et al., 2005).
5.3. TNBC biomarkers for assessment of prognosis and
therapy targeting
Parameters like the proliferating index, ploidity, presence of
p53, cytokeratins, HER1, and numerous other molecular alter-
ations, may also be useful for prognostic evaluation, for pre-
dicting therapeutic response and for guiding patient
management.
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Given the poor outcome of TNBC despite cytotoxic treat-
ment, alternative approaches are currently explored for possi-
ble application at the clinical level (Table 1).
5.3.1. HER1
HER1 (EGFR) is a receptor tyrosine kinase, that belongs to the
HER family of transmembrane receptors. HER1 gene is located
on 7q12 and its protein product e 170-kD glycoprotein e plays
an important role in cell proliferation, migration and protec-
tion against apoptosis mediated by subsequent activation of
intracellular pathways. After binding of epidermal growth
factor (EGF), the HER1 receptor can dimerize with other mem-
bers of the HER family, and it has to create homoe or hetero-
dimers to be functionally active (Hynes and Lane, 2005).
Increased HER1 expression is detected in about 40% of
breast carcinomas. Particularly, HER1 expression is higher
(up to 80%) in TNBC and metaplastic carcinoma (mostly
basal-like), where it possibly substitutes ineffective, but other-
wise major proliferation/survival pathways of breast cancer
induced by expression and activation of HER2, ER and PR pro-
teins. Currently, however, HER1 gene status is not used in clin-
ical practice to guide therapy in breast cancer. HER1 protein
could be targeted by monoclonal antibodies and/or synthetic
tyrosine kinase inhibitors (TKIs). Monoclonal antibodies
(cetuximab, panitumumab) are now clinically used in the
treatment of colorectal cancer and head and neck carcinoma.
TKIs are also important in the therapy of pancreatic and non-
small cell lung cancer.
Given the subset of TNBC which overexpresses EGFR (Viale
et al., 2009), targeting EGFR seems to be a rational approach.Al-
though cetuximab monotherapy has little clinical activity, in
combination with chemotherapy it may enhance tumor re-
sponse (Corkery et al., 2009; Carey et al., 2008). HER1 targeted
treatment with cetuximab in breast cancer has not produced
satisfactory resultsprobablybecauseof theactivationofdown-
stream signaling pathways (Shiu et al., 2008) or because of in-
adequate patient selection. Evaluation of the results of
studies testing TKIs (erlotinib, gefitinib) in breast cancer indi-
cated that HER1 proteinmust be present in targeted tumor tis-
sue to obtain valuable treatment results (Agrawal et al., 2005).
Furthermore, itmightbebetter to targetmore thanoneof these
receptors simultaneously.Thus,HER1assessmentcould reveal
a particular group of breast cancer patientswith probably good
response to HER1 targeted therapy.
5.3.2. TOP2A
TOP2A gene is located on 17q21e22, encoding topoisomerase
II alpha, which appears to be a molecular target for anthracy-
clines and hence is predictive of response to anthracycline
therapy. Good response to anthracyclines is associated with
TOP2A amplification, while deletion may be accompanied by
resistance. (Burgess et al. (2008) identified in a nonselected se-
ries, TOP2A expression levels as major determinants of re-
sponse to doxorubicin, which is a topoisomerase II inhibitor,
and showed that suppression of TOP2A levels produces resis-
tance to doxorubicin in vitro and in vivo.
Recent publications describe TOP2A amplification in
2.7e8.8% of HER2 non-amplified breast cancers (Knoop et al.,
2005). Adjuvant anthracycline treatment of TNBC patients
was shown to be associated with poor response in patients
with low expression of TOP2A protein. Microarray expression
analysis indicated that in a subgroup of TNBC there is a signif-
icant downregulation in PTEN and TOP2A which might partly
explain observed differences in response to chemotherapy in
TNBC (Weigelt et al., 2009). It should be noted, however, that
patients with a pathologic complete response to anthracy-
cline-based neoadjuvant chemotherapy had a good prognosis
regardless of subtype (Carey et al., 2007).
5.3.3. c-Myc
c-Myc is amajor transcription factor that encodesnuclearDNA
binding proteins that regulate cell growth, transformation, an-
giogenesis, cell-cycle control and apoptosis; c-Myc is directly
involved in regulating up to 15% of all human genes. c-Myc
amplification is one of the most frequently detected aberra-
tions in breast cancer. Amplification is clearly associated with
poorprognosis. InER-positivebreast cancer cells c-Mycexpres-
sion is under the regulation of estrogen, but in ER-negative/PR-
negative cells c-Myc constitutive expression level is usually
high.C-MYCproteinmayaffect the response to chemotherapy,
probably through DNA damage response regulation (Aulmann
et al., 2006; Corzo et al., 2006). BRCA1 is linked to transcriptional
regulation through interactionwithMyc.Hence, theMycrole in
BRCA1-associated breast cancer makes it an important target
in basal-like/triple-negative breast cancers.
It was found that only 4% of basal-like carcinomas showed
Myc amplification, compared to 8.75% and 10.7% of luminal
and HER2 tumors, respectively (Rodriguez-Pinilla et al.,
2007). Myc amplification displayed a significant association
with shorter metastasis-free and overall survival and proved
to be an independent prognostic factor in multivariate sur-
vival analysis. Thus, Myc amplification is not associated
with “basal-like” phenotype and proved to be an independent
prognostic factor for breast cancer patients treated with
anthracycline-based chemotherapy.
Conflicting results were obtained using microarray tech-
nology and performing a detailed kinetic study of genes that
respond toMYCNorMYCNDeltaMBII induction in primary hu-
man fibroblasts (Chandriani et al., 2009). An overlapping set of
398 genes was designated as “Core MYC Signature” and used
for further analysis. Comparison to a panel of breast cancers
revealed a strong concordance in gene expression between
the Core MYC Signature and the basal-like breast tumor sub-
type. This concordance was supported by the higher average
level of Myc expression in the same tumor samples. The
Core MYC Signature has clinical relevance as this profile can
be used to deduce an underlying genetic program that is likely
to contribute to a clinical phenotype and may predict clinical
responsiveness to drugs that are designed to disrupt Myc-me-
diated phenotypes.
5.3.4. VEGF receptor
Targeting angiogenesis by the monocloncal antibody bevaci-
zumab, added to paclitaxel, was shown to be beneficial in
terms of prolonged progression free survival (from 5.9 to 11.8
months) in a randomized phase III trial which included pa-
tients with both ER- and PR-positive, as well as ER- and PR-
negative disease. The majority of patients in this study were
HER2-negative and in the subset analysis ER-/PR-positive
and negative patients had a similar benefit frombevacizumab.
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In the neoadjuvant setting preliminary results from a non-
randomized phase II study have been reported which added
bevacizumab to cisplatinum. Effects were modest (complete
pathological response in 15%) while toxicity was considerable
(Ryan et al., 2009). Also, the effects of the small molecule TKI
sunitinib, which targets angiogenesis by binding the intracel-
lular domain of cell surface receptors, is modest in metastatic
breast cancer and is achieved at the price of significant toxic-
ity (Burstein et al., 2008). In a recently presented randomized
phase II trial it was shown that the addition of the another
TKI, sorafenib, to capecitabine increased progression free sur-
vival from 4.1 to 6.4 months compared to capecitabine mono-
therapy, again at the cost of considerable toxicity (Baselga
et al., 2009a). Of note, these studies with TKIs have not been
specifically designed for patients with TNBC.
5.3.5. The role of PARP inhibition
Oneof the promising newagents for the treatment of TNBCare
poly(ADP-ribose) polymerase (PARP) inhibitors. A subset of
PARPs is specifically involved in the detection of single strand
breaks and the recruitment of base excision repair elements.
In cells with alterations in BRCA function, as is often seen in
TNBC, DNA repair processes are largely dependent on PARPs.
Inhibition of PARP in these cells ultimately leads to cell death
(McCabe et al., 2006; Farmer et al., 2005). Phase I data for the
PARP inhibitor olaparib (AZD2281) suggest antitumoreffective-
ness in cancers associated with the BRCA1 or BRCA2mutation
(Fong et al., 2009). Preliminary results of a recent randomized
phase II study with the PARP inhibitor BSI-201, combined
with carboplatin and gemcitabine inmetastatic TNBC, showed
significantly improved clinical benefit rate, progression free
survival and overall survival (O’Shaughnessy et al., 2009).
In conclusion, the development of targeted agents is ur-
gently needed for patients with TNBC. Although promising
agents are being developed, no targeted treatment is yet avail-
able for routine clinical practice.
6. The promise of multidimension technological
approaches
Themultiplicity of interacting related factors across the entire
genome, the integration of pathways responsible for molecu-
lar and pathological factors, and the evolution of imaging ap-
proaches, require handling of redundant network interactions
(Fig. 2) rather than simple linear systems, to design more ro-
bust prognostic and predictive models and treatment algo-
rithms for TNBC and other breast cancer subtypes
(Goldhirsch et al., 2009).
Powerful technologies allowing us to take a more compre-
hensive overview of these multiple events are represented by
multivariate data analysis tools and integration of their re-
sults into a suitable systems biology approach.
6.1. Multivariate analysis of multi-modal, multi-
dimensional ‘omics’ data
In the search for biomarkers for breast cancer diagnosis and
recognition of subtypes, such as TNBC, for predictive markers
of response to treatment, and in the attempt to understand
the biological processes/pathways involved in breast cancer
(which could also lead to new biomarkers and therapy tar-
gets), high dimensional data are frequently used. These data
result from the different modern ‘omics’ related analyses
(e.g. microarrays in genomics, mass spectrometry combined
with some kind of separation, such as liquid chromatography
(LC), proteomics or NMR-based metabolomics). Multivariate
data analysis techniques are especially suited for this kind
of high and multi-dimensional data sets, in order to improve
medical knowledge discovery and integrate various sources
of biomedical information (Fig. 3). However, analysis and inte-
gration of (bio)medical data remain a challenging task because
of the highly complex nature and the large diversity of the
data. Therefore, these approaches, which include datamodel-
ing, data visualization and data mining, require a multidisci-
plinary research environment, unifying expert knowledge
from the field of medicine, biochemistry, bioinformatics, biol-
ogy, chemistry, machine learning and statistics. Data analysis
processes and, in particular, the integration of heterogeneous
biomedical information provide improved prevention, diag-
nosis and treatment of disease (e.g. cancer), since the technol-
ogy enables to better understand the underlying biological
relations. Discovery of these relations results in the develop-
ment of new screening techniques and strategies in the early
diagnosis of cancer, including tools for themonitoring and in-
terpretation of disease progression to expand the possibilities
and effectiveness of already existing therapies. There is an in-
creasing interest in using biological characteristics to subcat-
egorize cancer within a histological class to provide an
improved diagnostic system. For instance, breast tumors
could be classified into subtypes, having distinct differences
in gene expression patterns, by means of multivariate
Figure 3 e The flow, analysis and integration of multi-dimensional
molecular, biological and clinical data from different biomedical
sources leading to a new classification system, diagnostic tools and
predictive models in breast cancer.
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analysis techniques (Perou et al., 2000, 1999). In addition, evi-
dence has been reported that the incorporation of gene ex-
pression signatures into clinical risk stratification can refine
prognosis, resulting in optimized therapeutic strategies for
breast cancer (Acharya et al., 2008).
In the context of breast cancer all kinds of studies are per-
formed using ‘Omic’ data. Most studies involved one type of
data, mostly targeted at classification: healthy versus tumor,
benign versus tumor, good prognosis versus bad prognosis,
etc. Regarding for instance transcriptomic data, Chen et al.
(2009) recently combined this data with prior knowledge
from already known pathways in order to improve prediction
(they applied supervised principal component analysis (PCA)
to aggregate genes in so-called supergenes which are mostly
related to outcome). Proteomics data is widely used in breast
cancer recognition. An overview has been recently presented
by Gast et al. (2009), based onmeasurements in variousmatri-
ces like serum, plasma, nipple aspirate fluid, saliva, etc., al-
though the data are multivariate and high dimensional
advanced multivariate techniques are rarely used (see e.g.
Belluco et al., 2007). An additional problem was the relative
low number of samples involved. Furthermore, most of the
emphasis was on classification and less on identification of
the peaks involved. Metabolites are, in contrast to proteins,
much easier to identify. Altered metabolic activities of cancer
cells have been observed in many studies. Data in these stud-
ies result from mass spectrometry, and in vivo and ex-vivo
MRS (e.g. HR-MAS MRS of breast cancer tissues). An overview
of ex-vivo MRS studies is presented by Sitter et al. (2009).
Again, also in these studies relative simple univariate statisti-
cal tests are used to differentiate benign from cancer tissues
concentrating on choline related peaks. A broader overview
of the applications and perspectives of metabolomics is pre-
sented by Claudino et al. (2007). Multivariate techniques (Par-
tial Least Squares, Probabilistic Neural Networks, Support
Vector Machines) are applied in e.g. Bathen et al. (2007) on
HR-MAS spectra of breast cancer tissue biopsies, in Woo
et al. (2009) using endogenous steroids and nucleosides profil-
ing from GCeMS and LC-MS measurements of urine, and in
Henneges et al. (2009) using a limited set of metabolites from
LC-MS spectra of urine samples. Combining the data and in-
formation resulting from the various ‘omics’ techniques is
expected to improve prediction and classification. An example
of this kind of studies is presented in Chuang et al. (2007). The
authors applied a protein-network-based approach to analyze
the expression profiles of the two cohorts of breast cancer pa-
tients previously reported by two other groups. The proteine
protein interaction network information was extracted from
yeast data from literature. Still mostly statistical techniques
were applied to combine the information, after which logistic
regression was used to classify the patient data. An improved
accuracy was achieved compared to the original articles.
Although having their value in the diagnosis, sub-classifi-
cation and prognosis prediction of breast cancer, most of
these studies provided just limited or partial additional insight
on the complex biological processes involved in breast tumor
formation, the biological differences underlying the various
types of breast tumor and prognosis, and the processes influ-
encing the response differences of the various therapies. Re-
cent functional genomic and proteomic approaches include
proteineprotein, proteineDNA or other ‘compo-
nentecomponent’ interaction mapping (interactome map-
ping), systematic phenotypic analyses (phenome mapping)
and transcript or protein localization mapping (localizome
mapping). ‘Omic’ approaches have already been applied to
many biological processes, leading to large lists of genes, pro-
teins and metabolites potentially involved in the correspond-
ing biological processes. As stated earlier, an improvement is
expected in combining the data and the results of the various
single ‘omics’ approaches leading to an approach within Sys-
tems Biology called “top-down”modeling of the biological pro-
cesses. Examples of studies more or less aiming at this goal
are in Pujana et al. (2007), related to breast cancer and in
Erg}un et al. (2007), related to prostate cancer, whereas Nam
et al. (2009) is on the border between the application of various
data sources to improve classification and the use of these
various sources to obtain better insight. In Nam et al. (2009),
gene expression data sets of breast cancer and normal sub-
jects, transcriptional regulation information and metabolic
pathway information from appropriate databases were com-
bined. Using statistics the authors tried to find altered metab-
olism (altered pathways) which then lead to a set of potential
biomarkers. The latter were then tested in urine samples of
various types of breast cancer patients and healthy individ-
uals. Six biomarkers appeared to be statistically different,
but the area under the receiver operating characteristic
(ROC) curve improved when the biomarkers were combined
using multivariate classifiers. Beside this, the candidate bio-
markers were tested for potential use as indicators of cancer
progression. Pujana et al. (2007) started from four known
breast cancer-associated genes and their products, BRCA1
and BRCA2 and ATM and CHEK2, called ‘reference genes/pro-
teins’, and used data from gene transcript abundance mea-
surements from samples of healthy human tissues or organs
and three cell-lines, to find genes which potentially are func-
tionally associated (using correlation). Next, these potential
functional associations were investigated and ranked by inte-
gration with functional associations found in largely non-
overlapping ‘Omic’ data sets by using interologous functional
relationships from four species. This ultimately has led to
genes/proteins which later were proven to have a functional
relationship with the reference genes/proteins. Erg}un et al.
(2007) used an approach called mode-of-action by network
identification (MNI). The goal is to find transcript (genes)
which are mostly inconsistent with ‘normal’ regulatory gene
networks and which could be mediators of a disease. These
‘normal’ regulatory gene networks are first trained using
a large set of microarray expression data from 13 projects
spanning 7 cancer types by training a relative simple mathe-
matical model. PCAwas applied to reduce themassive dimen-
sions of the data. Then using test data from three types of
prostate cancer, those genes were identified which could po-
tentially be mediators for each type. Shen et al. (2009) devel-
oped a technique which could be used in this context. They
developed a latent variable model to allowmultiple data types
for the purpose of integrative clustering. Additional progress
in Systems Biology is expected from bioinformatic and che-
mometric techniques, which can handle and intelligently ex-
plore and apply the complex multi-modal multi-dimensional
‘omics’ data.
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An essential aspect of the use ofmultivariate analysis tools
in clinical applications is setting up research studies at more
than one medical center. A multi-center approach allows re-
searchers to address a larger population, which is decisive
for a better understanding of the disease and the underlying
biological relations (Garcia-Gomez et al., 2009). Depending
on the disease, the number of data is often limited. Large scale
multi-center data collection overcomes the problem of sparse
data, scattered over local centers’ databases and potential bias
due to single-center effects. Therefore, intelligent multivari-
ate analysis should be applied to a centralized collection of
multi-center data or to a distributed database, where each
node represents a single center. Furthermore, analysis of
multi-center data, including different types of data, requires
the introduction of a common terminology, which is related
to the design of ontologies. In addition, the data of the differ-
ent centers have to be compatible, demanding a fixed protocol
for data acquisition and acquisition conditions. In conclusion,
results from the analysis of multi-center studies can poten-
tially unravel the biological dynamics of disease and improve
healthcare.
An illustration of the use of multivariate analysis in multi-
center studies is the development of decision support tools
within the context of the European projects IOTA, eTUMOUR
and HealthAgents (http://www.etumour.net; http://www.
healthagents.net; Van Holsbeke et al., 2007; Timmerman
et al., 2005). The multi-center project IOTA focuses on the
characterization of ovarian tumors. Ultrasound images and
clinical data from 1066 patients were acquired during the pe-
riod 1999e2002 (Van Holsbeke et al., 2007). Mathematical
models to predict the risk of malignancy were developed
and were internally and externally validated on nearly 2000
patients with adnexal tumors in 20 centers throughout the
world during the periods 2002e2005 and 2005e2007, respec-
tively (Timmerman et al., 2005). Currently, the IOTA project in-
vestigates the incorporation of proteomics data in the process
of pattern analysis. The multidisciplinary eTUMOUR and
HealthAgents projects aimed to develop and validate decision
support tools for brain cancer diagnostics by combiningmulti-
modalmulti-dimensional clinical data, ‘Omic’ data (genomics,
metabolomics, transcriptomics) and bioimaging data (in vivo
magnetic resonance spectroscopy (MRS), magnetic resonance
spectroscopic imaging (MRSI), magnetic resonance imaging
(MRI), which were acquired over multiple centers from all
over the world and stored in a database system (Lluch-Ariet
et al., 2008). Models for tumor diagnosis were developed
from these data and included artificial neural networks, sup-
port vector machines, discriminant analysis and nearest
neighbour classifiers (Bishop, 1995; Duda et al., 2001; Vapnik,
2002). Furthermore, thesemodels were included in a graphical
user interface tomake them available for clinicians. The exist-
ing breast cancer consortia either focus on ‘Omic’ data only
(such as METAcancer (http://www.metacancer-fp7.eu), Meta-
Bre (http://www.metabre.org), TRANS-BIG (http://www.
breastinternationalgroup.org/Research/TRANSBIG.aspx), or
on imaging data only (such as MammoGrid (http://www.
cems.uwe.ac.uk/cccs/project.php?name¼mammogrid) using
mammographic data). This overview enlightens the need for
setting up similar European-wide or worldwide consortia for
breast cancer diagnostics by combining all data, from the
nano-level (‘Omic’ data) up to the macro-level (in vitro, in
vivo) so as to further improve breast cancer diagnostics and
prognosis.
6.2. The power of systems biology approaches in cancer
research
Systems biology is an area that has both providedmany prom-
ises to support understanding of cellular regulation and that
requires new ways of producing and analyzing data. Experi-
mental research and computational modeling of biological
processes ranges from small regulatory networks to full-scale
genomic models. Depending on the specific question, they are
of different value. Clinically relevant studies needmodels that
provide testable predictions.
Network models comprise interaction information of all
compounds of a type such as proteins or genes.Model analysis
may reveal insight into hidden relations. A respective study
has, for example, linked breast cancer susceptibility with cen-
trosome dysfunction (Pujana et al., 2007): by combining ex-
pression profiles with functional genomic and proteomic
data, 118 genes were aligned with potential functions. Among
those genes is the one coding for hyaluronan-mediated motil-
ity receptor, HMMR, and a functional association with the
breast cancer-associated gene BRCA1 was predicted. Another
large-scale study has systematically linked disorders and
genes associated with the diseases (Goh et al., 2007).
Signaling pathways by which cells receive and process ex-
ternal information are a subject of intensive study in experi-
mental and computational systems biology. Amongst the
most carefully studied pathways are the EGFR (Samaga
et al., 2009; Schoeberl et al., 2002), Wnt (Lee et al., 2003), Jak/
STAT (Swameye et al., 2003), TGFb (Zi and Klipp, 2007;
Schmierer et al., 2008), and NFkB pathways. As example for
the relevance of signaling pathways for breast cancer, it has
been demonstrated recently that TGFb signaling switches
breast cancer cell motility (Giampieri et al., 2009). The models
are frequently formulated as sets of ordinary differential
equations (ODEs) describing the temporal evolution of the in-
volved components and their activity. They serve various pur-
poses, among them most notably (i) just to understand their
architecture and the observed dynamics and (ii) to rationalize
the interdependence of independently measured data such as
ligand supply, phosphorylation states, protein interactions,
and gene expression effects (e.g. Chen et al., 2009). Dynamic
features such as the effect of positive or negative feedback
(e.g., Bluthgen et al., 2009; Kholodenko, 2000), or crosstalk be-
tween different pathways (Borisov et al., 2009) have been stud-
ied extensively.
Cell cycle progression is highly regulated and failure to re-
spond to checkpoints or external signals may be a first step to
cancer. Mathematical modeling of cell cycle has initially fo-
cused on model organisms such as frog eggs or yeast (Chen
et al., 2004, 2000), but also on mammalian cells (Alfieri et al.,
2009). Again, these models first of all serve to test our under-
standing of the structure or wiring of cell cycle machinery, but
they also analyze detailed questions such as the effect of mu-
tants or of unreplicated DNA on cell cycle progression (Zwolak
et al., 2009). While including more and more details of the pro-
tein machinery and other components into models, the
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regulation of cell cycle by nutrition, signaling, or checkpoints
becomes more and more predictable based on model
simulations.
Development, stem cell differentiation and cell reprogram-
ming have been described with mathematical models on dif-
ferent levels. The Davidson lab has delivered gene regulation
networks of Xenopus eggs (Davidson et al., 2003) with ever in-
creasing detailedness over last years, which contain activat-
ing and inhibiting influences of developmental genes on
each other and also provide a link to regulatory signaling path-
ways such asWnt pathway. Translating this static representa-
tion into a dynamic model is a challenge on its own, but
appears feasible with upcoming data. A computational ODE
model describes the dynamics of the core network governing
stemcellness and cellular differentiation (Chickarmane and
Peterson, 2008).
Target prediction is an important goal of systems biology
approaches. Based on sufficiently well described networks
and properties of the compounds’ interaction, mathematical
models can be useful to predict targets for treatment and
test the outcome of different target positions, treatment
strengths, target combinations or temporal combination sce-
narios (Fitzgerald et al., 2006; Schulz et al., 2009). This field is
only in its infancy, since there is still a lack of sufficiently
well understood networks, however there are already very
promising examples among signaling pathway models, such
as the study of the ErbB network with sensitivity analysis
(Schoeberl et al., 2009), which identified ErbB3 as a key node
in response to ligands. Boolean modeling (assigning activity
values of 0 and 1 to nodes which are updated in time based
on their inputs from other nodes) of the ErbB receptor regu-
lated G1/S transition has revealed new potential targets in
case of de novo trastuzumab resistance in breast cancer.
Chronotherapy is a field that is based on the fact that living
beings exhibit various rhythms, such as cell cycle, circadian or
annual rhythms. Circadian rhythms have been investigated,
their components identified (Ueda et al., 2005) and their dy-
namics described with mathematical models (Brown et al.,
2008). It has turned out that cancer treatment has different ef-
fects if supplied at different times of the day (Levi and Schibler,
2007).
Taken together, different directions of systems biology
combining experimental and computational analysis have al-
ready made first promising contributions to understand as-
pects of cellular regulation and dysfunction. Further
investigations need precise and reproducible data and sensi-
blemathematical descriptions to produce predictive and help-
ful models in cancer research (Aebersold et al., 2009).
7. Conclusions
7.1. Challenges and limitations
A better understanding of pathological mechanisms of TNBC
onset and progression, including the still unclear association
with BRCA1 mutations, and the causes of TNBC phenotypic
heterogeneity is expected to improve diagnosis, prognosis,
treatment and prevention of these cancers. Amajor limitation
to a robust delineation of differences between basal-like and
triple-negative breast cancer subtypes is the present lack of
consensus on immunohistochemical assays to be used in
the clinical setting, and the still unclear relationships between
traditional diagnostic classifiers and genomic aberrations.
7.2. Limitations of the present therapeutic options
Largerprospectiveclinical trialsareneeded tooptimize chemo-
therapy treatments and predict the response of different TNBC
subgroups to cytotoxic agents. Although promising agents are
presentlybeingdevelopedandtested, no targeted treatmental-
gorithms are as yet available for TNBC at the clinical level.
7.3. Perspectives
Improved awareness of the significance of gene expression
signatures combined with a holistic characterization of cell
signaling pathways’ aberrations, may lead to more suitable
prognostic and predictive models, to more adequate algo-
rithms of therapy targeting, and improved molecular imaging
approaches for earlier and non invasive tumor responsemon-
itoring. Well designed and rigorous studies are needed to re-
solve still conflicting or partial results.
A possible breakthrough in the field may derive from appli-
cation of robust multivariate data analyses on well pro-
grammed collections of multi-modal, multi-dimensional data
sets provided by the simultaneous use of different ‘omics’ at
pre-clinical and clinical level, and processing of the results in
the frame of a suitable Systems Biology approach.
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